Viral Vectors And Plasmid DNA Manufacturing Market (By Type: Adeno associated virus, Lentivirus, Adenovirus, Retrovirus, Plasmid DNA; By Workflow: Upstream Processing, Downstream Processing; By Application: Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology, Research Applications; By End-Use: Pharmaceutical and Biopharmaceutical Companies, Research Institutes; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1. Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type, 2020-2027

7.1.1.    Adenovirus

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Retrovirus

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Plasmid DNA

7.1.3.1.        Market Revenue and Forecast (2016-2027)

7.1.4.    AAV

7.1.4.1.        Market Revenue and Forecast (2016-2027)

7.1.5.    Lentivirus

7.1.5.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

8.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type, 2020-2027

8.1.1.    Upstream Processing

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Downstream Processing

8.1.2.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

9.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type, 2020-2027

9.1.1.    Antisense & RNAi

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Gene Therapy

9.1.2.1.        Market Revenue and Forecast (2016-2027)

9.1.3.    Cell Therapy

9.1.3.1.        Market Revenue and Forecast (2016-2027)

9.1.4.    Vaccinology

9.1.4.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-use Type

10.1.        Viral Vectors & Plasmid DNA Manufacturing Market, By End-use Type, 2020-2027

10.1.1.  Pharmaceutical and Biopharmaceutical Companies

10.1.1.1.      Market Revenue and Forecast (2016-2027)

10.1.2.  Research Institutes

10.1.2.1.      Market Revenue and Forecast (2016-2027)

Chapter 11.      Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease Type

11.1.        Viral Vectors & Plasmid DNA Manufacturing Market, By Disease, 2020-2027

11.1.1.  Cancer

11.1.1.1.      Market Revenue and Forecast (2016-2027)

11.1.2.  Genetic Disorders

11.1.2.1.      Market Revenue and Forecast (2016-2027)

11.1.3.  Infectious Diseases

11.1.3.1.      Market Revenue and Forecast (2016-2027)

Chapter 12.      Global Viral Vectors & Plasmid DNA Manufacturing  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.1.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.1.3.  Market Revenue and Forecast, By Application (2016-2027)

12.1.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.1.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.1.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.1.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.1.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.1.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.1.8.  Rest of North America

12.1.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.1.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.1.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.1.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.1.8.5.      Market Revenue and Forecast, By Disease (2016-2027)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.2.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.2.3.  Market Revenue and Forecast, By Application (2016-2027)

12.2.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.2.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.2.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.2.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.2.7.  Market Revenue and Forecast, By End-use (2016-2027)

12.2.8.  Market Revenue and Forecast, By Disease (2016-2027)

12.2.9.  Germany

12.2.9.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.2.9.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.2.9.3.      Market Revenue and Forecast, By Application (2016-2027)

12.2.10.               Market Revenue and Forecast, By End-use (2016-2027)

12.2.11.               Market Revenue and Forecast, By Disease (2016-2027)

12.2.12.               France

12.2.12.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.2.12.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.2.12.3.   Market Revenue and Forecast, By Application (2016-2027)

12.2.12.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.2.13.               Market Revenue and Forecast, By Disease (2016-2027)

12.2.14.               Rest of Europe

12.2.14.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.2.14.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.2.14.3.   Market Revenue and Forecast, By Application (2016-2027)

12.2.14.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.2.15.               Market Revenue and Forecast, By Disease (2016-2027)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.3.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.3.3.  Market Revenue and Forecast, By Application (2016-2027)

12.3.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.3.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.3.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.3.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.3.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.3.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.8.  China

12.3.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.3.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.3.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.3.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.3.9.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.10.               Japan

12.3.10.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.3.10.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.3.10.3.   Market Revenue and Forecast, By Application (2016-2027)

12.3.10.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.3.10.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.3.11.               Rest of APAC

12.3.11.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.3.11.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.3.11.3.   Market Revenue and Forecast, By Application (2016-2027)

12.3.11.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.3.11.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.4.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.4.3.  Market Revenue and Forecast, By Application (2016-2027)

12.4.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.4.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.4.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.4.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.4.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.4.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.8.  North Africa

12.4.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.4.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.4.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.4.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.4.9.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.10.               South Africa

12.4.10.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.4.10.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.4.10.3.   Market Revenue and Forecast, By Application (2016-2027)

12.4.10.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.4.10.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.4.11.               Rest of MEA

12.4.11.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.4.11.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.4.11.3.   Market Revenue and Forecast, By Application (2016-2027)

12.4.11.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.4.11.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.5.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.5.3.  Market Revenue and Forecast, By Application (2016-2027)

12.5.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.5.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.5.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.5.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.5.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.5.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.5.8.  Rest of LATAM

12.5.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.5.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.5.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.5.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.5.8.5.      Market Revenue and Forecast, By Disease (2016-2027)

Chapter 13.  Company Profiles

13.1.              Novasep

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Aldevron

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              MerckWaismanBiomanufacturing

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Creative Biogene

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              The Cell and Gene Therapy Catapult

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Cobra Biologics

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              uniQure N.V.

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Addgene

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              FUJIFILM Holdings Corporation

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Oxford Biomedicaplc

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

13.11.           Takara Bio Inc.

13.11.1.               Company Overview

13.11.2.               Product Offerings

13.11.3.               Financial Performance

13.11.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1. About Us

15.2 Glossary of Terms